Enfusion Ownership
| ENFN Stock | USD 11.07 0.02 0.18% |
Enfusion |
Enfusion Stock Ownership Analysis
About 97.0% of the company shares are held by institutions such as insurance companies. The company has Price/Earnings To Growth (PEG) ratio of 2.35. Enfusion had not issued any dividends in recent years. Enfusion, Inc. provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. Enfusion Inc. was incorporated in 2021 and is headquartered in Chicago, Illinois. Enfusion Inc operates under SoftwareApplication classification in the United States and is traded on New York Stock Exchange. It employs 892 people. To learn more about Enfusion call the company at 312 253 9800 or check out https://www.enfusion.com.Besides selling stocks to institutional investors, Enfusion also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Enfusion's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Enfusion's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Enfusion Quarterly Liabilities And Stockholders Equity |
|
Enfusion Insider Trades History
About 5.0% of Enfusion are currently held by insiders. Unlike Enfusion's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Enfusion's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Enfusion's insider trades
Enfusion Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Enfusion is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Enfusion backward and forwards among themselves. Enfusion's institutional investor refers to the entity that pools money to purchase Enfusion's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-12-31 | 1.1 M | Citadel Advisors Llc | 2024-12-31 | 1 M | Wellington Management Company Llp | 2024-12-31 | 1 M | Azora Capital Lp | 2024-12-31 | 1 M | Nellore Capital Management Llc | 2024-12-31 | 868.1 K | Dimensional Fund Advisors, Inc. | 2024-12-31 | 798.9 K | Impax Asset Management Group Plc | 2024-09-30 | 676.9 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 521 K | Northern Trust Corp | 2024-12-31 | 443.1 K | Iconiq Capital, Llc | 2024-12-31 | 14 M | Brown Capital Management, Llc | 2024-12-31 | 7.1 M |
Enfusion Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Enfusion insiders, such as employees or executives, is commonly permitted as long as it does not rely on Enfusion's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Enfusion insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Enfusion Outstanding Bonds
Enfusion issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Enfusion uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Enfusion bonds can be classified according to their maturity, which is the date when Enfusion has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| ENFRAG 5375 30 DEC 30 Corp BondUS29280LAA17 | View | |
| ENELIM 2875 12 JUL 41 Corp BondUS29280HAB87 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Enfusion Corporate Filings
F4 | 7th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 3rd of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 31st of January 2025 Other Reports | ViewVerify | |
| 30th of January 2025 Other Reports | ViewVerify |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enfusion. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. To learn how to invest in Enfusion Stock, please use our How to Invest in Enfusion guide.You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Is Application Software space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enfusion. If investors know Enfusion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enfusion listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.82) | Earnings Share 0.03 | Revenue Per Share | Quarterly Revenue Growth 0.139 | Return On Assets |
The market value of Enfusion is measured differently than its book value, which is the value of Enfusion that is recorded on the company's balance sheet. Investors also form their own opinion of Enfusion's value that differs from its market value or its book value, called intrinsic value, which is Enfusion's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enfusion's market value can be influenced by many factors that don't directly affect Enfusion's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enfusion's value and its price as these two are different measures arrived at by different means. Investors typically determine if Enfusion is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enfusion's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.